Vectus Biosystems Ltd
Research Vectus Biosystems Ltd (VBS) on Bullrun: market cap AUD 9.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVBS
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 9.28M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 9.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.03 | n/a | n/a | n/a |
| FY2024 | n/a | -AUD 2.34M | -AUD 2.10M | n/a | -0.04 | AUD 808.97K | AUD 28.93K | AUD 1.49M |
| FY2023 | n/a | -AUD 3.45M | -AUD 2.37M | n/a | -0.07 | AUD 2.95M | AUD 70.21K | AUD 3.52M |
| FY2022 | n/a | -AUD 3.99M | -AUD 4.46M | n/a | -0.12 | AUD 1.28M | AUD 6.02M | -AUD 3.53M |
| FY2021 | AUD 180 | -AUD 4.28M | -AUD 3.26M | 100.0% | n/a | AUD 5.78M | AUD 7.67M | -AUD 2.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 9.28M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vectus Biosystems Ltd's market cap?
Vectus Biosystems Ltd's market capitalization is AUD 9.28M.
What does Vectus Biosystems Ltd do?
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases.